Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review.
Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review.
复制标题
DOI：
10.1155/2012/104317
复制
发表时间：
2012
影响因子：
--
通讯作者：
Hagerman RJ
中科院分区：
文献类型：
--
作者：
Indah Winarni T;Chonchaiya W;Adams E;Au J;Mu Y;Rivera SM;Nguyen DV;Hagerman RJ
患有脆性X综合征（FXS）的幼儿通常会出现与感觉过度觉醒相关的焦虑、易怒和多动。然而，对于5岁以下患有FXS的儿童，没有记录有效的药物建议。我们通过对45名12-50个月的FXS儿童的图表回顾来检查数据，使用马伦早期学习量表（MSEL）进行基线和纵向评估。所有儿童在第一次就诊时都有临床焦虑水平，基于MSEL评分的语言延迟，以及相似的早期学习综合（ELC）评分。自闭症谱系障碍（ASD）的发病率在两组中相似。有11名儿童接受舍曲林治疗，这些患者与34名未接受舍曲林治疗的儿童进行回顾性比较。治疗组和未治疗组分别在18 - 44个月（平均值26.9，SD 7.99）和12 - 50个月（平均值29.94，SD 8.64）时进行基线评估。舍曲林治疗组的语言表达和接受发育的平均改善率显著高于对照组（分别为P < 0.0001和P = 0.0071）。这些数据支持了对FXS患儿进行舍曲林治疗的对照试验的必要性。
Young children with fragile X syndrome (FXS) often experience anxiety, irritability, and hyperactivity related to sensory hyperarousal. However, there are no medication recommendations with documented efficacy for children under 5 years old of age with FXS. We examined data through a chart review for 45 children with FXS, 12–50 months old, using the Mullen Scales of Early Learning (MSEL) for baseline and longitudinal assessments. All children had clinical level of anxiety, language delays based on MSEL scores, and similar early learning composite (ELC) scores at their first visit to our clinic. Incidence of autism spectrum disorder (ASD) was similar in both groups. There were 11 children who were treated with sertraline, and these patients were retrospectively compared to 34 children who were not treated with sertraline by chart review. The baseline assessments were done at ages ranging from 18 to 44 months (mean 26.9, SD 7.99) and from 12 to 50 months (mean 29.94, SD 8.64) for treated and not treated groups, respectively. Mean rate of improvement in both expressive and receptive language development was significantly higher in the group who was treated with sertraline (P < 0.0001 and P = 0.0071, resp.). This data supports the need for a controlled trial of sertraline treatment in young children with FXS.